TITLE

Antiretroviral Drugs in Pediatric HIV-Infected Patients

AUTHOR(S)
Phelps, B. Ryan; Rakhmanina, Natella
PUB. DATE
June 2011
SOURCE
Pediatric Drugs;2011, Vol. 13 Issue 3, p175
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Antiretroviral (ARY) therapy has been shown to achieve high therapeutic efficacy in treating pediatric HLV disease. The delivery of affordable, child friendly, and easy to store and administer ARV drugs is key to the successful management of HIV in children. In recent years, significant progress has been made in scaling up the access to pediatric ARY therapy among children worldwide. Despite the improved ARV drug access, multiple challenges remain concerning palatability and efficient delivery of ARV drugs to children from infancy into adolescence. Data are limited regarding developmental changes in pharmacokinetics of individual ARV drugs, and pediatric and adult fixed-dose combinations. This review provides a practical discussion regarding the pharmacokinetics of ARY agents in pediatric HIV-infected patients, as well as the practical challenges of currently available formulations, such as palatability of liquid formulations, challenges of crushing tablets, and using adult and pediatric fixed-dose combinations.
ACCESSION #
62095823

 

Related Articles

  • Plasma HIV Load and Proviral DNA Decreases After Two Standard Antiretroviral Regimens in HIV-Positive Patients Naive to Antiretrovirals. Torti, Carlo; Quiros-Roldan, Maria Eugenia; Cologni, Giuliana; Nichelatti, Michele; Ceresoli, Francesca; Pinti, Marcello; Nasi, Milena; Cossarizza, Andrea; Lapadula, Giuseppe; Costarelli, Silvia; Manca, Nino; Gargiulo, Franco; Magoni, Michele; Carosi, Giampiero // Current HIV Research;Jan2008, Vol. 6 Issue 1, p43 

    (i) To compare early decrease of HIV plasma viral load (pVL) after two standard combinations of highly active antiretroviral therapy (HAART). (ii) To evaluate variations of proviral HIV-DNA load on conditions of sustained pVL undetectability. Two different sub-studies of a multicentre...

  • CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1–infected individuals. Ahuja, Sunil K.; Kulkarni, Hemant; Catano, Gabriel; Agan, Brian K.; Camargo, Jose F.; Weijing He; O'Connell, Robert J.; Marconi, Vincent C.; Delmar, Judith; Eron, Joseph; Clark, Robert A.; Frost, Simon; Martin, Jeffrey; Ahuja, Seema S.; Deeks, Steven G.; Little, Susan; Richman, Douglas; Hecht, Frederick M.; Dolan, Matthew J. // Nature Medicine;Apr2008, Vol. 14 Issue 4, p413 

    The basis for the extensive variability seen in the reconstitution of CD4+ T cell counts in HIV-infected individuals receiving highly active antiretroviral therapy (HAART) is not fully known. Here, we show that variations in CCL3L1 gene dose and CCR5 genotype, but not major histocompatibility...

  • Immune reconstitution syndrome leading to fatal invasive cerebral aspergillosis: case report.  // Reactions Weekly;7/16/2005, Issue 1060, p6 

    The article presents a case of an HIV-infected man with fatal invasive cerebral aspergillosis associated with immune reconstitution syndrome after starting antiretroviral therapy. The man received other medical treatment after weeks of antiretroviral therapy. Medical history and condition of the...

  • Providing antiretroviral treatment in Thailand.  // Report on the Global HIV/AIDS Epidemic: UNAIDS - 2004;1/1/2004, p106 

    The article offers information on the antiretroviral treatment program in Thailand. According to the author, lower drug prices have contributed to a fivefold increase in the number of human immunodeficiency virus (HIV)-positive patients receiving antiretroviral treatment in the country. It was...

  • Antiretrovirals: HIV, hepatic impairment and HBV/HCV.  // WHO Drug Information;2005, Vol. 19 Issue 3, p214 

    The article presents information on the established the HIV/Hepatitis Co-infection Cohort Collaboration to plan to obtain information on the hepatic safety of highly active antiretroviral treatment in co-infected patients. During 2002, the European Medicines Agency requested the marketing...

  • The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. Fumagalli, Luca; Zucchetti, Massimo; Parisi, Idria; Viganò, Maria Grazia; Zecca, Bruno; Careddu, Anna; D'Incalci, Maurizio; Lazzarin, Adriano // Cancer Chemotherapy & Pharmacology;Jun2000, Vol. 45 Issue 6, p495 

    Purpose: To investigate the pharmacokinetics of liposomal daunorubicin (DaunoXome) administered alone or in combination with antiviral therapy including protease inhibitors (PI) to HIV-positive patients affected by Kaposi's sarcoma (KS). Patients and methods: A group of 18 patients with...

  • HAVE A HARRT.  // Gay Community News;Jun2007, Issue 210, p24 

    The article discusses the highly active anti-retroviral therapy (HAART) drugs and focuses on the reasons why people with HIV are floundering with such drugs. The HAART has revolutionized the treatment of HIV and its development have refined the revolution and mainly focused on minimising side...

  • Five-Year Outcomes of the China National Free Antiretroviral Treatment Program.  // Annals of Internal Medicine;8/18/2009, Vol. 151 Issue 4, pI-42 

    The article presents a study on the rate of recovery of patients in the National Free Antiretroviral Treatment Program in China after five years. It notes that 48,785 patients with HIV were enrolled in the program under the highly active antiretroviral therapy. It mentions that after 6 months of...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Oct2005, Vol. 19 Issue 10, p696 

    Reports several developments related to antiviral agents worldwide. Accounts on the reaction of HIV viral load to ritonavir-boosted atazanavir used as monotherapy; Analysis by Great Britain researchers on the benefit of highly active antiretroviral therapy when compared to no treatment in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics